UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000025010
Receipt No. R000028775
Scientific Title Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study)
Date of disclosure of the study information 2016/12/01
Last modified on 2021/09/02 (Ver. 7)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study)
Acronym Trimodality with Adjuvant Radiation in Stage N2-3A/3B Non-small Cell Lung Cancer
Scientific Title Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study)
Scientific Title:Acronym Trimodality with Adjuvant Radiation in Stage N2-3A/3B Non-small Cell Lung Cancer
Region
Japan

Condition
Condition Resectable Stage 3A-N2 Non-small Cell Lung Cancer
Classification by specialty
Pneumology Chest surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To clarify the feasibility of trimodality treatment with induction chemotherapy, radical surgery, and adjuvant radiation in stage 3A-N2 non-small cell lung cancer
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes feasibility
Key secondary outcomes response rate of induction chemotherapy, safety, progression free survival

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine Maneuver
Interventions/Control_1 Trimodality treatment with 3 course of induction chemotherapy with Carboplatin AUC5 and nab-Paclitaxel 100mg/m2, radical surgery more than lobectomy, adjuvant radiation 50Gy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria 1.Stage 3A non-small-cell lung cancer (NSCLC) with mediastinal lymph node metastasis (N2) confirmed pathologically without chest wall invasion
2.R0 radical surgery is expected after induction chemotherapy
3.Normal pulmonary function (%VC > 80%, FEV1% > 70%) within 56 days prior to consent
4.Chemotherapy-naive and radiotherapy-naive
5.20 - 75 years of age at enrollment
6.ECOG Performance Status 0-1
7.The latest clinical laboratory test within 28 days prior to enrollment meets the following all standard
Leukocyte count > 3,000/mm3
Hemoglobin > 10.0g/dl
Platelet > 100,000/mm3
Total bilirubin < 1.5mg/dl
Serum albumin > 3.0g/dl
AST/ALT < 100 IU
Creatinine < 1.2mg/dl
SpO2 > 95%
8.Patients providing the written informed consent for this trial
Key exclusion criteria 1.Evident unresectable extranodal lymph node involvement in CT scanning
2.Contraindication to either carboplatin or nab-paclitaxel
3.History of severe drug hypersensitivity
4.Impaired pulmonary function
5.Myocardial infarction within 6 months (180 days) prior to consent
6.Interstitial pneumonia, pulmonary fibrosis suspected or diagnosed within 56 days prior to consent
7.Administration of prednisolone > 10mg/day within 90 days prior to consent
8.Clinically severe heart diseases
9.Clinically severe psychiatric diseases
10.Uncontrollable diabetes mellitus
11.Clinically active infection
12.Any other severe complication
13.Active double malignancies
14.Pregnant, lactating or possibly pregnant
15.Any other unsuitable reasons judged by attending investigators
Target sample size 25

Research contact person
Name of lead principal investigator
1st name Masayoshi
Middle name
Last name Inoue
Organization Kyoto Prefectural University of Medicine
Division name Division of Thoracic Surgery, Department of Surgery
Zip code 6028566
Address Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-Ku ,Kyoto
TEL +81752515739
Email mainoue@koto.kpu-m.ac.jp

Public contact
Name of contact person
1st name Hiroaki
Middle name
Last name Tsunezuka
Organization Kyoto Prefectural University of Medicine
Division name Division of Thoracic Surgery, Department of Surgery
Zip code 6028566
Address Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-Ku ,Kyoto
TEL 075-251-5739
Homepage URL
Email tsune@koto.kpu-m.ac.jp

Sponsor
Institute Kyoto Prefectural University of Medicine
Institute
Department

Funding Source
Organization Kyoto Prefectural University of Medicine
Division of Thoracic Surgery, Department of Surgery
Organization
Division
Category of Funding Organization Local Government
Nationality of Funding Organization

Other related organizations
Co-sponsor Kyoto Prefectural University of Medicine
The Center for Quality Assurance in Research and Development
Name of secondary funder(s)

IRB Contact (For public release)
Organization Kyoto Prefectural University of Medicine, IRB
Address Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-Ku ,Kyoto
Tel 0752515337
Email rinri@koto.kpu-m.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 12 Month 01 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled 1
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 12 Month 15 Day
Date of IRB
2017 Year 10 Month 13 Day
Anticipated trial start date
2018 Year 11 Month 01 Day
Last follow-up date
2021 Year 06 Month 16 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 11 Month 27 Day
Last modified on
2021 Year 09 Month 02 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028775